LEADER 06310nam 2200433 450 001 9910616371103321 005 20230225005002.0 010 $a3-031-09058-6 035 $a(MiAaPQ)EBC7102141 035 $a(Au-PeEL)EBL7102141 035 $a(CKB)24950454100041 035 $a(OCoLC)1347760636 035 $a(EXLCZ)9924950454100041 100 $a20230225d2022 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aPsychosis and personality disorders $eunmet needs in early diagnosis and treatment /$fedited by Paola Rocca and Silvio Bellino 210 1$aCham, Switzerland :$cSpringer,$d[2022] 210 4$d©2022 215 $a1 online resource (161 pages) 311 08$aPrint version: Rocca, Paola Psychosis and Personality Disorders Cham : Springer International Publishing AG,c2022 9783031090578 327 $aIntro -- Contents -- 1: Trajectories Toward Bipolar Disorder or Schizophrenia in FEP and High-Risk Mental State -- 1.1 Introduction -- 1.2 Genetics -- 1.3 Cognitive Impairment -- 1.4 Neuroimaging -- 1.5 Prodromes -- 1.6 Conclusions -- References -- 2: New Strategies to Improve Cognitive Symptom Domain in the Treatment of Schizophrenia -- 2.1 Introduction -- 2.2 Pharmacological Treatment to Improve Cognitive Functioning in Schizophrenia -- 2.2.1 Cognitive Functioning in Schizophrenia: Focus on Treatment Management -- 2.2.2 Cognitive Functioning in Schizophrenia: Focus on Metabolic Profile -- 2.2.3 Cognitive Functioning in Schizophrenia: Focus on First- and Second-Generation Antipsychotics -- 2.2.4 Cognitive Functioning in Schizophrenia: Focus on Long-Acting Injectable (LAI) Antipsychotics -- 2.2.5 Cognitive Functioning in Schizophrenia: Focus on Antidepressants -- 2.2.6 Cognitive Functioning in Schizophrenia: Focus on New Pharmacological Targets -- 2.3 Non-pharmacological Interventions to Improve Cognitive Functioning in Schizophrenia: Focus on Cognitive Remediation -- 2.4 What Is Cognitive Remediation and How Does It Work? -- 2.5 Cognitive Remediation: Focus on Social and Nonsocial Cognition -- 2.5.1 Cognitive Remediation: Focus on Psychosocial Functioning -- 2.5.2 Cognitive Remediation: Focus on Clinical Symptoms -- 2.6 Conclusions and Future Directions -- References -- 3: Psychotic Disorders and Substance Abuse Comorbidity: Characteristics and Treatment -- 3.1 Introduction -- 3.2 Epidemiology -- 3.3 Psychosis and (Ab)use of Substances -- 3.3.1 Psychosis and Cannabis -- 3.3.2 Psychosis and (Met)Amphetamines -- 3.3.3 Psychosis and Alcohol -- 3.3.4 Psychosis and Tobacco -- 3.4 Mechanisms Underlying Comorbidity -- 3.4.1 Auto-Medication -- 3.4.2 Early Childhood Adversity. 327 $a3.4.3 Common Underlying Neurobiological Factors -- 3.5 Screening and Diagnosis on SUD -- 3.6 Treatment -- 3.6.1 General Aspects -- 3.6.2 Psychosocial Interventions -- 3.6.3 Pharmacological Aspects -- 3.6.3.1 Antipsychotic Medications -- 3.6.3.2 Medications Used for Substance Abuse Treatment -- Treatment of Alcohol Use Disorders -- Smoking -- Opiate Use Disorders -- 3.6.4 Organizational Aspects -- 3.7 Conclusions -- References -- 4: Recovery from Psychosis: Definition, Paradoxes, and Clinical Implications -- 4.1 Introduction -- 4.2 Historical Views of Outcome from Psychosis: The Rule and Alure of Pessimism -- 4.3 The Emergence of Recovery as the Expected Outcome from Psychosis -- 4.4 Two Emerging Challenges or Paradoxes from Research on Recovery from Psychosis -- 4.5 Metacognition and Paradoxes Posed by the Study of Recovery -- 4.6 General Implications for Recovery-Oriented Practice and Conclusions -- References -- 5: Cluster A Personality Disorders and Potential for Early Intervention in Psychosis: Challenges and Opportunities -- 5.1 Cluster A Personality Disorders (CAPD): Classification and Symptoms -- 5.2 Relationship between Cluster A Personality Disorders and Schizophrenia -- 5.3 Cluster A Personality Disorders and Clinically High-Risk States for Psychosis -- 5.4 Interventions for Treating Cluster A Personality Disorders -- 5.5 Pharmacological Interventions for Cluster A Personality Disorders -- 5.5.1 Non-pharmacological Interventions for Cluster A Personality Disorders -- 5.6 Challenges and Opportunities for Research and Treatment of Cluster A Personality Disorder -- 5.7 Conclusions -- References -- 6: Risk Factors of Early Onset of Borderline Personality Disorder: A Conceptual Model -- 6.1 Borderline Personality Disorder: A Complex Diagnosis -- 6.2 Environmental Factors -- 6.3 Temperament and Personality Traits. 327 $a6.4 Early Psychopathological Features -- 6.5 Brain Imaging Findings in Early-Onset BPD -- 6.6 Early Treatments -- 6.7 A Conceptual Model of Risk Factors for Early-Onset BPD -- References -- 7: Clinical Evaluation and Intervention of Emerging Psychosis: A Mentalization-Informed Perspective -- 7.1 SSPDs and Mentalizing: Is There a Connection? -- 7.2 Risk and Resilience in SSPD: A Developmental Account -- 7.2.1 Mentalizing in the Premorbid Period -- 7.2.2 Mentalizing in the CHR Period -- 7.3 Clinical Implications of an Integrative Mentalization-Informed Perspective on SSPDs -- 7.4 Conclusion -- References -- 8: Personality Disorders and Suicidality -- 8.1 Introduction -- 8.1.1 Personality Disorders and Suicidality -- 8.1.1.1 Developmental Trajectories of Self-injury Behaviors and Borderline Personality Disorders -- 8.1.1.2 Temperament and Character Correlates of Personality and Suicidality -- 8.1.2 Eysenck Personality Questionnaire -- 8.1.3 Temperament and Character Inventory -- 8.1.4 TEMPS-A -- 8.1.5 Shedler-Westen Assessment Procedure -- 8.1.6 The Big Five -- 8.2 Interpersonal Theory of Suicide -- 8.3 Conclusions -- References. 606 $aPersonality disorders 615 0$aPersonality disorders. 676 $a016.36229 702 $aRocca$b Paola 702 $aBellino$b Silvio 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910616371103321 996 $aPsychosis and Personality Disorders$93372659 997 $aUNINA